# Selara Drug Use Investigation (Regulatory Post Marketing Commitment Plan)

> **NCT00749775** · — · COMPLETED · sponsor: **Pfizer's Upjohn has merged with Mylan to form Viatris Inc.** · enrollment: 3338 (actual)

## Conditions studied

- Hypertension

## Interventions

- **DRUG:** Selara

## Key facts

- **NCT ID:** NCT00749775
- **Lead sponsor:** Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2008-06
- **Primary completion:** 2012-12
- **Final completion:** 2012-12
- **Target enrollment:** 3338 (ACTUAL)
- **Last updated:** 2020-12-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00749775

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00749775, "Selara Drug Use Investigation (Regulatory Post Marketing Commitment Plan)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00749775. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*